We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Waters Corporation (WAT - Free Report) reported third-quarter 2023 non-GAAP earnings of $2.84 per share, beating the Zacks Consensus Estimate by 10.94%. The bottom line increased 7.6% on a year-over-year basis.
Net sales of $711.7 million lagged the Zacks Consensus Estimate of $725 million. The figure rose 0.4% on a reported basis but declined 4% at constant currency year over year.
Waters benefited from the Wyatt acquisition, which contributed 4% to quarterly sales.
Top Line in Detail
Waters’ net sales figure can be categorized in four ways:
By Operating Segment: WAT operates under two organized segments, namely Waters and TA.
Waters Corporation Price, Consensus and EPS Surprise
The Waters segment (88.4% of net sales) generated sales worth $629.3 million, up 1% year over year. TA segment sales (11.6% of net sales) were $82.3 million, down 3.3% year over year.
By Products & Services: The division comprises three segments, namely Instruments, Services and Chemistry.
Instruments sales were $319.4 million, down 5% on a year-over-year basis.
Services sales were $263.6 million, which climbed 8% year over year. Chemistry sales totaled $128.7 million, flat year over year.
On a combined basis, the Services and Chemistry segments generated recurring revenues of $392.3 million, up 6% year over year.
By Markets: Waters serves three end markets, including Pharmaceutical, Industrial and Governmental & Academic.
The Pharmaceutical market generated sales of $421.5 million, up 4% on a year-over-year basis. Academic & Government generated $80.7 million, up 3% year over year.
The Industrial market’s sales were $209.4 million, down 6% year over year.
By Geography: Waters’ operating regions include Asia, the Americas and Europe.
Asia generated $238.2 million in sales, down 15% on a year-over-year basis. The company reported disappointing sales in China.
Sales in the Americas generated $275.5 million, up 7% year over year. The United States registered a 12% improvement year over year in sales.
Europe generated $198 million in sales, up 15% year over year.
Operating Details
In the third quarter, non-GAAP selling and administrative expenses were $155.7 million, down 3.6% year over year. As a percentage of net sales, the figure declined 90 basis points (bps) on a year-over-year basis.
Research and development spending of $40 million declined 7.8% year over year. As a percentage of net sales, the figure declined 50 bps.
Adjusted operating margin was 31.5%, which expanded 380 bps year over year.
Balance Sheet & Cash Flow
As of Sep 30, 2023, cash, cash equivalents and investments were $337.3 million, down from $330.6 million as of Jul 1, 2023.
Waters generated cash from operations of $157.8 million in the reported quarter, significantly up from $18.1 million in the prior quarter.
WAT recorded a free cash flow of $122.7 million in the third quarter.
Guidance
For fourth-quarter 2023, Waters expects non-GAAP earnings in the range of $3.52-$3.62 per share.
Management anticipates net sales to decline 8-5% on a constant-currency basis. WAT projects sales to decline roughly 1.5% due to unfavorable foreign exchange fluctuations. Also, the Wyatt transaction is estimated to increase sales by 4%.
On a reported basis, total sales are predicted to decline in the 6-3% band.
For 2023, Waters anticipates non-GAAP earnings in the range of $11.65-$11.75 per share. This includes a foreign exchange headwind of 3.5%.
Waters projects 2023 net sales to decline between 2% and 1% on a constant-currency basis. The Wyatt transaction is expected to increase sales by 2.5%.
On a reported basis, total sales are suggested to be between flat to down 1%.
Zacks Rank & Stocks to Consider
Currently, Waters has a Zacks Rank #4 (Sell).
Waters shares have lost 20.2% year to date, underperforming the Zacks Medical sector’s decrease of 10.2%.
Image: Bigstock
Waters (WAT) Q3 Earnings Beat Estimates, Revenues Rise Y/Y
Waters Corporation (WAT - Free Report) reported third-quarter 2023 non-GAAP earnings of $2.84 per share, beating the Zacks Consensus Estimate by 10.94%. The bottom line increased 7.6% on a year-over-year basis.
Net sales of $711.7 million lagged the Zacks Consensus Estimate of $725 million. The figure rose 0.4% on a reported basis but declined 4% at constant currency year over year.
Waters benefited from the Wyatt acquisition, which contributed 4% to quarterly sales.
Top Line in Detail
Waters’ net sales figure can be categorized in four ways:
By Operating Segment: WAT operates under two organized segments, namely Waters and TA.
Waters Corporation Price, Consensus and EPS Surprise
Waters Corporation price-consensus-eps-surprise-chart | Waters Corporation Quote
The Waters segment (88.4% of net sales) generated sales worth $629.3 million, up 1% year over year. TA segment sales (11.6% of net sales) were $82.3 million, down 3.3% year over year.
By Products & Services: The division comprises three segments, namely Instruments, Services and Chemistry.
Instruments sales were $319.4 million, down 5% on a year-over-year basis.
Services sales were $263.6 million, which climbed 8% year over year. Chemistry sales totaled $128.7 million, flat year over year.
On a combined basis, the Services and Chemistry segments generated recurring revenues of $392.3 million, up 6% year over year.
By Markets: Waters serves three end markets, including Pharmaceutical, Industrial and Governmental & Academic.
The Pharmaceutical market generated sales of $421.5 million, up 4% on a year-over-year basis. Academic & Government generated $80.7 million, up 3% year over year.
The Industrial market’s sales were $209.4 million, down 6% year over year.
By Geography: Waters’ operating regions include Asia, the Americas and Europe.
Asia generated $238.2 million in sales, down 15% on a year-over-year basis. The company reported disappointing sales in China.
Sales in the Americas generated $275.5 million, up 7% year over year. The United States registered a 12% improvement year over year in sales.
Europe generated $198 million in sales, up 15% year over year.
Operating Details
In the third quarter, non-GAAP selling and administrative expenses were $155.7 million, down 3.6% year over year. As a percentage of net sales, the figure declined 90 basis points (bps) on a year-over-year basis.
Research and development spending of $40 million declined 7.8% year over year. As a percentage of net sales, the figure declined 50 bps.
Adjusted operating margin was 31.5%, which expanded 380 bps year over year.
Balance Sheet & Cash Flow
As of Sep 30, 2023, cash, cash equivalents and investments were $337.3 million, down from $330.6 million as of Jul 1, 2023.
Waters generated cash from operations of $157.8 million in the reported quarter, significantly up from $18.1 million in the prior quarter.
WAT recorded a free cash flow of $122.7 million in the third quarter.
Guidance
For fourth-quarter 2023, Waters expects non-GAAP earnings in the range of $3.52-$3.62 per share.
Management anticipates net sales to decline 8-5% on a constant-currency basis. WAT projects sales to decline roughly 1.5% due to unfavorable foreign exchange fluctuations. Also, the Wyatt transaction is estimated to increase sales by 4%.
On a reported basis, total sales are predicted to decline in the 6-3% band.
For 2023, Waters anticipates non-GAAP earnings in the range of $11.65-$11.75 per share. This includes a foreign exchange headwind of 3.5%.
Waters projects 2023 net sales to decline between 2% and 1% on a constant-currency basis. The Wyatt transaction is expected to increase sales by 2.5%.
On a reported basis, total sales are suggested to be between flat to down 1%.
Zacks Rank & Stocks to Consider
Currently, Waters has a Zacks Rank #4 (Sell).
Waters shares have lost 20.2% year to date, underperforming the Zacks Medical sector’s decrease of 10.2%.
Aveanna Healthcare (AVAH - Free Report) , GoodRx (GDRX - Free Report) and Exscientia (EXAI - Free Report) are some better-ranked stocks that investors can consider in the broader Zacks Medical sector, each sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Aveanna shares have gained 103.8% year to date. AVAH is set to report its third-quarter 2023 results on Nov 9.
GoodRx shares have returned 14.2% year to date. GDRX is set to report its third-quarter 2023 results on Nov 9.
Exscientia shares have declined 37.6% year to date. EXAI is set to report its third-quarter 2023 results on Nov 9.